Transplantation of spinal cord–derived neural stem cells for ALS: Analysis of phase 1 and 2 trials

• Published in: Neurology Vol. 87; no. 4; pp. 392 - 400
• Main Authors: Glass, Jonathan D, Hertzberg, Vicki S, Boulis, Nicholas M, Riley, Jonathan, Federici, Thais, Polak, Meraida, Bordeau, Jane, Fournier, Christina, Johe, Karl, Hazel, Tom, Cudkowicz, Merit, Atassi, Nazem, Borges, Lawrence F, Rutkove, Seward B, Duell, Jayna, Patil, Parag G, Goutman, Stephen A, Feldman, Eva L
• Format: Journal Article
• Language: English
• Published: United States American Academy of Neurology 26-07-2016; Lippincott Williams & Wilkins
• Subjects: Adult; Age of Onset; Amyotrophic Lateral Sclerosis - therapy; Cervical Vertebrae; Female; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Lumbosacral Region; Male; Middle Aged; Neural Stem Cells - transplantation; Spinal Cord - surgery; Stem Cell Transplantation - adverse effects; Stem Cell Transplantation - methods; Treatment Outcome
• ISSN: 0028-3878; 1526-632X
• DOI: 10.1212/WNL.0000000000002889

OBJECTIVE:To test the safety of spinal cord transplantation of human stem cells in patients with amyotrophic lateral sclerosis (ALS) with escalating doses and expansion of the trial to multiple clinical centers.
METHODS:This open-label trial included 15 participants at 3 academic centers divided into 5 treatment groups receiving increasing doses of stem cells by increasing numbers of cells/injection and increasing numbers of injections. All participants received bilateral injections into the cervical spinal cord (C3-C5). The final group received injections into both the lumbar (L2-L4) and cervical cord through 2 separate surgical procedures. Participants were assessed for adverse events and progression of disease, as measured by the ALS Functional Rating Scale–Revised, forced vital capacity, and quantitative measures of strength. Statistical analysis focused on the slopes of decline of these phase 2 trial participants alone or in combination with the phase 1 participants (previously reported), comparing these groups to 3 separate historical control groups.
RESULTS:Adverse events were mostly related to transient pain associated with surgery and to side effects of immunosuppressant medications. There was one incident of acute postoperative deterioration in neurologic function and another incident of a central pain syndrome. We could not discern differences in surgical outcomes between surgeons. Comparisons of the slopes of decline with the 3 separate historical control groups showed no differences in mean rates of progression.
CONCLUSIONS:Intraspinal transplantation of human spinal cord–derived neural stem cells can be safely accomplished at high doses, including successive lumbar and cervical procedures. The procedure can be expanded safely to multiple surgical centers.
CLASSIFICATION OF EVIDENCE:This study provides Class IV evidence that for patients with ALS, spinal cord transplantation of human stem cells can be safely accomplished and does not accelerate the progression of the disease. This study lacks the precision to exclude important benefit or safety issues.